Imagine a smart health kit that acts like a 24/7 guardian for people with severe cancer. It uses a special watch and a skin patch to track pain and muscle loss, sending the data to an AI that helps doctors tweak nutrition and exercise plans in real-time. It's like having a personalized health coach and a doctor's eye on the patient even when they are at home.
Advanced pancreatic cancer patients suffer from severe pain and muscle loss (cachexia) that current palliative care struggles to manage in real-time. There is a lack of continuous, objective data to help doctors personalize nutrition and activity plans.
An end-to-end beta system consisting of a multi-sensor smartwatch, a remote ultrasound patch, AI monitoring algorithms, and mobile apps for patients and caregivers.
If you are a wearable manufacturer dealing with a lack of specialized clinical use-cases for sensors — this project developed a multi-sensor smartwatch and ultrasound patch that monitors sarcopenia and pain. This allows for the creation of high-value, prescription-grade monitoring hardware.
If you are a software provider dealing with the difficulty of creating actionable decision support for palliative care — this project developed AI algorithms for continuous remote monitoring. This enables the delivery of personalized care plans based on real-time patient evidence.
If you are a clinic operator dealing with high patient stress and inefficient symptom management — this project developed patient and caregiver mobile applications. This reduces the burden on families and improves the quality of life for patients.
Based on available project data, specific pricing is not mentioned, but the project is investigating the cost-effectiveness of the intervention as a secondary outcome.
The project is testing the system across a five-centre randomized clinical trial (RELEVIUM-RCT) with 132 patients, suggesting a path toward multi-center clinical scaling.
Based on available project data, specific licensing terms are not provided, though a Joint Controllers Agreement for data sharing has been signed.
The project runs from 2022-09-01 to 2026-11-30, indicating that final efficacy results and recommendations will be available toward the end of 2026.
The system integrates via patient and caregiver mobile applications that facilitate communication between the patient and the doctor.
The consortium is highly commercially oriented with 19 partners, featuring a strong industry presence of 8 companies (42% industry ratio), including 7 SMEs. This balance of 4 universities and 4 research institutions alongside industry players suggests a high priority on translating the AI and hardware components into marketable products.
Contact Universitaetmedizin der Johannes Gutenberg-Universitaet Mainz
Contact us to explore licensing opportunities for the AI-guided monitoring algorithms.
